Sartorius BIA Separations and Exopharm sign joint research agreement to develop integrated technology for large-scale exosome production Partnership will address technical challenges of large-scale, high-efficiency purification of therapeutic exosomes for non-viral drug delivery Programme combines novel technologies and expertise – LEAP exosome purification technology from Exopharm and BIA’s CIM monoliths Melbourne, Australia and […]
Link to PDF of release Introduction: ‘The time for exosomes as an essential part of modern medicines is with us’ explains Dr Ian Dixon, founder and CEO of Exopharm. Advances made by Exopharm with its exosome technologies coincides with heightened interest in mRNA therapeutics [1]. Drug-delivery is the main hurdle holding back many potential mRNA […]
Key Highlights Exopharm has a new Investor Presentation available to shareholders and investors on our website 2 lead Genetic Medicine (GM) programs have been selected for our in-house product development investment These products have been selected considering potential future commercial value and as a way to showcase exosomes as a non-viral nanoparticle ‘chassis’ to overcome drug-delivery problems […]
Scientists at Exopharm have collaborated with Associate Professor Jason Howitt and his research team at Swinburne University of Technology to probe the molecular processes that occur with aging. NAD+ (nicotinamide adenine dinucleotide), an essential metabolite for energy metabolism, declines with age, however extracellular vesicles (EVs) released by the body during exercise can boost NAD+ levels […]
We are pleased to announce that our Expert View article titled “Extracellular Vesicle Engineering: Optimising Nature’s Non-Immunogenic, Drug Delivery Platform” has been published in ONdrugDelivery. You can check out this Expert View article from Exopharm’s Research and Innovation Manager, Dr Anna Cifuentes-Rius here . Dr Cifuentes-Rius discusses how to take advantage of EV’s capacity to […]
With a rapidly growing global interest in the superpower of exosomes, major pharmaceutical deals and foundational patents, Exopharm is poised to become an essential part of the modern medicine ecosystem. As the only listed exosome company on the ASX, and one of a small number of exosome companies listed globally, Australian biopharma Exopharm (ASX:EX1) […]
Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial services are designed to seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA Future […]
